grant
Cancer Immunology
Organization ICAHN SCHOOL OF MEDICINE AT MOUNT SINAILocation NEW YORK, UNITED STATESPosted 1 Aug 2015Deadline 31 Jul 2030
NIHUS FederalResearch GrantFY2025Animal ModelAnimal Models and Related StudiesAwardBiologic ModelsBiological ModelsBreast CancerCAR T cellsCAR modified T cellsCAR-TCAR-TsCCSGCITE sequencingCITE-seqCITEseqCRISPRCRISPR editing screenCRISPR screenCRISPR-based screenCRISPR/Cas systemCRISPR/Cas9 screenCancer Center Support GrantCancer PatientCancer TreatmentCancersCatchment AreaCell BodyCellsCellular Indexing of Transcriptomes and Epitopes by SequencingCheckpoint inhibitorClinical TrialsClustered Regularly Interspaced Short Palindromic RepeatsColorectal CancerCytotoxic cellDendritic CellsDevelopmentDirect CostsDysfunctionEducationEducational aspectsElementsEquilibriumFunctional disorderFundingGenomicsGoalsGrantHepatic CancerHumanImmuneImmune DiseasesImmune DisordersImmune DysfunctionImmune MarkersImmune System DiseasesImmune System DisorderImmune System DysfunctionImmune System and Related DisordersImmune TargetingImmune checkpoint inhibitorImmune mediated therapyImmune responseImmunesImmunologic DiseasesImmunologic MarkersImmunological DiseasesImmunological DysfunctionImmunological System DysfunctionImmunologically Directed TherapyImmunologyImmunosuppressionImmunosuppression EffectImmunosuppressive EffectImmunotherapeutic agentImmunotherapyInnate Immune SystemIntrinsic factorInvestigatorsK lymphocyteLeadershipLesionMacrophageMalignant Breast NeoplasmMalignant CellMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant TumorMalignant Tumor of the LungMalignant neoplasm of liverMalignant neoplasm of lungMalignant neoplasm of prostateMalignant prostatic tumorMediatingModel SystemModelingModern ManMolecularMultiple MyelomaMyeloid-derived suppressor cellsMφNK CellsNatural Killer CellsPD-1 antibodyPD-L1 antibodyPD1 antibodyPaperPathway interactionsPatientsPhysiopathologyPlasma-Cell MyelomaPopulationPre-Clinical ModelPreclinical ModelsProstate CAProstate CancerProstate malignancyPublishingPulmonary CancerPulmonary malignant NeoplasmRefractoryResearch PersonnelResearchersResistanceRiskRoleSamplingSingle cell seqStromal CellsT cell based immune therapyT cell based therapeuticsT cell based therapyT cell directed therapiesT cell immune therapyT cell immunotherapyT cell targeted therapeuticsT cell therapyT cell treatmentT cell-based immunotherapyT cell-based treatmentT cells for CART cellular immunotherapyT cellular therapyT lymphocyte based immunotherapyT lymphocyte based therapyT lymphocyte therapeuticT lymphocyte treatmentT-CellsT-LymphocyteT-cell therapeuticsT-cell transfer therapyTechnologyTestingTranslatingTranslationsVeiled CellsWorkaCTLA-4aCTLA-4 antibodiesaCTLA4aPD-1aPD-L1aPD-L1 antibodiesaPD1adoptive T cell transferadoptive T lymphocyte transferadoptive T-cell therapyanti programmed cell death 1anti programmed cell death ligand 1anti programmed cell death protein ligand 1anti-CTLA-4anti-CTLA-4 antibodiesanti-CTLA4anti-CTLA4 antibodiesanti-PD-(L)1anti-PD-1anti-PD-1 Abanti-PD-1 antibodiesanti-PD-1 monoclonal antibodiesanti-PD-L1anti-PD-L1 antibodiesanti-PD-L1 monoclonal antibodiesanti-PD1anti-PD1 Abanti-PD1 antibodiesanti-PD1 monoclonal antibodiesanti-PDL-1anti-PDL1anti-PDL1 antibodiesanti-cancer therapyanti-programmed cell death protein 1anti-programmed cell death protein 1 antibodiesanti-programmed death-1 antibodyantiPD-1antiPD-L1balancebalance functioncancer carecancer cellcancer immunologycancer microenvironmentcancer therapycancer-directed therapycellular indexing of transcriptomes and epitopes by single cell sequencingchimeric antigen T cell receptorchimeric antigen receptor (CAR) T cellschimeric antigen receptor Tchimeric antigen receptor T cellschimeric antigen receptor fusion protein T-cellschimeric antigen receptor modified T cellsclinical applicabilityclinical applicationclinical investigationclustered regularly interspaced short palindromic repeats screendesigndesigningdevelopmentalhost responsehuman diseaseimmune check point inhibitorimmune drugsimmune suppressionimmune suppressive activityimmune suppressive functionimmune system responseimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based biomarkersimmune-based therapeuticsimmune-based therapiesimmune-based treatmentsimmuno therapyimmunologic therapeuticsimmunological biomarkersimmunological markersimmunoresponseimmunosuppressive activityimmunosuppressive functionimmunosuppressive myeloid cellsimmunosuppressive responseimmunotherapeuticsimmunotherapy agentimprovedin silicoinnate immune functioninnovateinnovationinnovativeliver cancerliver malignancylung cancermalignancymalignant breast tumormalignant liver tumormembermodel of animalmyeloid suppressor cellsmyeloid-derived suppressive cellsmyelomamyelomatosisneoplasm immunologyneoplasm/cancernew approachesnew technologynovelnovel approachesnovel strategiesnovel strategynovel technologiespathophysiologypathwaypre-clinicalpreclinicalprogramsrecruitresistantresponseresponse to therapyresponse to treatmentsingle cell next generation sequencingsingle cell sequencingsocial rolespatial RNA sequencingspatial gene expression analysisspatial gene expression profilingspatial resolved transcriptome sequencingspatial transcriptome analysisspatial transcriptome profilingspatial transcriptome sequencingspatial transcriptomicsspatially resolved transcriptomicsspatio transcriptomicssuppressive myeloid cellstherapeutic T-cell platformtherapeutic responsetherapy responsethymus derived lymphocytetranslationtreatment responsetreatment responsivenesstumortumor growthtumor immunologytumor microenvironmentα-CTLA-4α-CTLA4αCTLA-4αCTLA4αPD-1αPD-L1αPD-L1 antibodiesαPD1αPDL1
Description preview
The Cancer Immunology (CI) Program of The Tisch Cancer Institute (TCI) is comprised of 25 members whose common goal is to identify mechanisms underlying immune-mediated dysregulation in the TME and to develop novel approaches to overcome immune suppressive pathways. The CI membership represents 9 Departments and Institutes. As of 2024, CI program…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click